Vitrolife: Conference Call Interim Report

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:

Invitation to attend Vitrolife’s (STO: VITR.ST) conference call regarding presentation of the interim report for the period January-September 2008. The presentation will be held in Swedish.

The press release for Vitrolife’s interim report will be released in good time before 3.00 p.m. CET on October 22.

Before the conference call, slides will be available at the company web page, www.vitrolife.com, under the section Investors/News (the Swedish page).

A recorded version of the presentation will be available for seven days on number +46 8 505 203 33, access code 813897.

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media) and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 140 employees and the company’s products are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and there are subsidiaries in Sweden, USA, Australia and Italy. The Vitrolife share is listed on the OMX Nordic Exchange Stockholm's Nordic Small Cap list.

Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate identity number 556354-3452.

Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Homepage: www.vitrolife.com.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://www.cisionwire.com

Vitrolife
Anna Ahlberg, CFO
Phone +46 31 721 80 13 or +46 708 22 80 13